Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.
Mark S. Roberts, MD, MPP
Advertisement
Articles by Mark S. Roberts, MD, MPP
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Pneumococcal Polysaccharide Vaccine Among Healthcare Workers During an Influenza Pandemic
Published: March 9th 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Boosting RSV Vaccination in Older Adults Could Save Thousands
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
5
